Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Proteomic Signature of BMI and Risk of Type 2 Diabetes

Xuan Wang, Hao Ma, Minghao Kou, Yoriko Heianza, Vivian Fonseca, Lu Qi

Diabetes 2025;74(2):234–242

https://doi.org/10.2337/db24-0329

Published: 19 November 2024

View article titled, Proteomic Signature of BMI and Risk of Type 2 Diabetes

Meeting Abstracts

152-OR: Sex Differences in Metabolomics and Risk of Coronary Heart Disease in Type 2 Diabetes

YILIN YOSHIDA, DANTING LI, XIANG LI, VIVIAN FONSECA, FRANCK MAUVAIS-JARVIS, LU QI

Diabetes 2024;73(Supplement_1):152-OR

https://doi.org/10.2337/db24-152-OR

Published: 14 June 2024

View article titled, 152-OR: Sex Differences in Metabolomics and Risk of Coronary Heart Disease in Type 2 Diabetes

Meeting Abstracts

916-P: SGLT2 Inhibitors and Parkinson’s Disease (PD) Risk in Older Populations with Type 2 Diabetes (T2D)

JINGCHUAN GUO, HUILIN TANG, HUI SHAO, YING LU, LIZHENG SHI, VIVIAN FONSECA, YI GUO, JIANG BIAN

Diabetes 2024;73(Supplement_1):916-P

https://doi.org/10.2337/db24-916-P

Published: 14 June 2024

View article titled, 916-P: SGLT2 Inhibitors and Parkinson’s Disease (PD) Risk in Older Populations with Type 2 Diabetes (T2D)

Meeting Abstracts

1047-P: Estimating QALY-Based Price Ranges for Diabetes Drugs under IRA Negotiation

PIAOPIAO LI, JIEUN LEE, XIN HU, K M VENKAT NARAYAN, GUILLERMO UMPIERREZ, LIZHENG SHI, VIVIAN FONSECA, MOHAMMED K. ALI, HUI SHAO

Diabetes 2024;73(Supplement_1):1047-P

https://doi.org/10.2337/db24-1047-P

Published: 14 June 2024

View article titled, 1047-P: Estimating QALY-Based Price Ranges for Diabetes Drugs under IRA Negotiation

Meeting Abstracts

1269-P: Cumulative Effect of Early-Onset Type 2 Diabetes on Cardiac Dysfunction—The Coronary Artery Risk Development in Young Adults (CARDIA) Study

YILIN YOSHIDA, KEITH C. FERDINAND, DAVID AGUILAR, VIVIAN FONSECA

Diabetes 2024;73(Supplement_1):1269-P

https://doi.org/10.2337/db24-1269-P

Published: 14 June 2024

View article titled, 1269-P: Cumulative Effect of Early-Onset Type 2 Diabetes on Cardiac Dysfunction—The Coronary Artery Risk Development in Young Adults (CARDIA) Study

Meeting Abstracts

560-P: Optimizing Vision Care for Diabetes Patients—Interprofessional Initiatives to Combat Clinical Inertia in the Management of Diabetic Retinopathy and Diabetic Macular Edema

MARGERY J. TAMAS, MICHAEL BEYER, RICHARD S. BEASER, VIVIAN FONSECA, ANDREW A. MOSHFEGHI, HEATHER N. DREW

Diabetes 2024;73(Supplement_1):560-P

https://doi.org/10.2337/db24-560-P

Published: 14 June 2024

View article titled, 560-P: Optimizing Vision Care for Diabetes Patients—Interprofessional Initiatives to Combat Clinical Inertia in the Management of Diabetic Retinopathy and Diabetic Macular Edema

Meeting Abstracts

1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes—Soli De-escalation

FRANCESCO GIORGINO, FELIPE LAUAND, SR., SORALY SERVERA, XUAN LI, ZOLTÁN TAYBANI, ALICE Y.Y. CHENG, VIVIAN FONSECA, AMAR TEBAIBIA, INAN ANAFOROGLU

Diabetes 2024;73(Supplement_1):1867-LB

https://doi.org/10.2337/db24-1867-LB

Published: 14 June 2024

View article titled, 1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes—Soli De-escalation

Meeting Abstracts

829-P: Outcomes with Finerenone in People with CKD and T2D by Baseline Insulin Resistance—A FIDELITY Subgroup Analysis

THOMAS EBERT, STEFAN ANKER, LUIS M. RUILOPE, PAOLA FIORETTO, VIVIAN FONSECA, GUILLERMO UMPIERREZ, ANDREAS L. BIRKENFELD, ROBERT LAWATSCHECK, CHARLIE SCOTT, KATJA ROHWEDDER, PETER ROSSING

Diabetes 2023;72(Supplement_1):829-P

https://doi.org/10.2337/db23-829-P

Published: 20 June 2023

View article titled, 829-P: Outcomes with Finerenone in People with CKD and T2D by Baseline Insulin Resistance—A FIDELITY Subgroup Analysis

Meeting Abstracts

1005-P: Developing a Machine-Learning–Based Prediction Model for Diabetes Duration Using Information from Electronic Health Records

DAWEI GUAN, PIAOPIAO LI, VIVIAN FONSECA, LIZHENG SHI, MOHAMMED K. ALI, JITHIN SAM VARGHESE, RODRIGO M. CARRILLO-LARCO, MASOUD ROUHIZADEH, ALMUT G. WINTERSTEIN, TIANZE JIAO, HUI SHAO

Diabetes 2023;72(Supplement_1):1005-P

https://doi.org/10.2337/db23-1005-P

Published: 20 June 2023

View article titled, 1005-P: Developing a Machine-Learning–Based Prediction Model for Diabetes Duration Using Information from Electronic Health Records

Meeting Abstracts

1225-P: Biomarkers in Prediabetes Reflecting Sex Varying Pathways of Cardiovascular Risk

YILIN YOSHIDA, ZHIPENG CHEN, CHANGWEI LI, VIVIAN FONSECA, FRANCK MAUVAIS-JARVIS

Diabetes 2023;72(Supplement_1):1225-P

https://doi.org/10.2337/db23-1225-P

Published: 20 June 2023

View article titled, 1225-P: Biomarkers in Prediabetes Reflecting Sex Varying Pathways of Cardiovascular Risk

Meeting Abstracts

881-P: Heterogenous Effects of SGLT2 Inhibitors on Nephrolithiasis in Older Adults with Type 2 Diabetes

YUJIA LI, HUI SHAO, YI GUO, YONGKANG ZHANG, VIVIAN FONSECA, LIZHENG SHI, JIANG BIAN, ALMUT G. WINTERSTEIN, JINGCHUAN GUO

Diabetes 2023;72(Supplement_1):881-P

https://doi.org/10.2337/db23-881-P

Published: 20 June 2023

View article titled, 881-P: Heterogenous Effects of SGLT2 Inhibitors on Nephrolithiasis in Older Adults with Type 2 Diabetes

Meeting Abstracts

1006-P: Distributional Cost-Effectiveness Analysis of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) and Tirzepatide Compared with Sulfonylureas (SU) in People with Inadequately Controlled Type 2 Diabetes (T2D)

PIAOPIAO LI, DAWEI GUAN, MOHAMMED K. ALI, K.M. VENKAT NARAYAN, VIVIAN FONSECA, GUILLERMO UMPIERREZ, LIZHENG SHI, JIANG BIAN, YI GUO, ALMUT G. WINTERSTEIN, JINGCHUAN GUO, HUI SHAO

Diabetes 2023;72(Supplement_1):1006-P

https://doi.org/10.2337/db23-1006-P

Published: 20 June 2023

View article titled, 1006-P: Distributional Cost-Effectiveness Analysis of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) and Tirzepatide Compared with Sulfonylureas (SU) in People with Inadequately Controlled Type 2 Diabetes (T2D)

Meeting Abstracts

1352-P: Ethnic Disparities in Diabetic Complications in the U.S.

YILIN YOSHIDA, VIVIAN FONSECA, YUANHAO ZU

Diabetes 2023;72(Supplement_1):1352-P

https://doi.org/10.2337/db23-1352-P

Published: 20 June 2023

View article titled, 1352-P: Ethnic Disparities in Diabetic Complications in the U.S.

Meeting Abstracts

824-P: Glycemic Improvement, Insulin Reductions, and Improved Body Weight 48 Weeks after Revita Duodenal Mucosal Resurfacing in T2D patients with Previously Inadequately Controlled Glucose Despite Multiple Glucose-Lowering Agents Including Insulin

VIVIAN FONSECA, JACQUES BERGMAN, ZEB I. SAEED, HARITH RAJAGOPALAN, BARBARA SORONDO, KELLY WHITE, HUI ZHANG, GELTRUDE MINGRONE

Diabetes 2023;72(Supplement_1):824-P

https://doi.org/10.2337/db23-824-P

Published: 20 June 2023

View article titled, 824-P: Glycemic Improvement, Insulin Reductions, and Improved Body Weight 48 Weeks after Revita Duodenal Mucosal Resurfacing in T2D patients with Previously Inadequately Controlled Glucose Despite Multiple Glucose-Lowering Agents Including Insulin

Meeting Abstracts

1196-P: Sex Difference in the Progression of Metabolic Syndrome Severity from Normoglycemia, Prediabetes, to Diabetes

YILIN YOSHIDA, ZHIPENG CHEN, ROBIN L. BAUDIER, MARIE KROUSEL-WOOD, AMANDA H. ANDERSON, VIVIAN FONSECA, FRANCK MAUVAIS-JARVIS

Diabetes 2022;71(Supplement_1):1196-P

https://doi.org/10.2337/db22-1196-P

Published: 01 June 2022

View article titled, 1196-P: Sex Difference in the Progression of Metabolic Syndrome Severity from Normoglycemia, Prediabetes, to Diabetes

Meeting Abstracts

418-P: Certain Patient Subgroups with Type 2 Diabetes May Benefit from Intensive Glycemic and Blood Pressure Control from Reductions in Major Adverse Cardiovascular Events (MACE) : A Machine Learning–Based Post Hoc Analysis of ACCORD Trial Data

HAMED KIANMEHR, PING ZHANG, NAYKKY SINGH OSPINA, LIZHENG SHI, VIVIAN FONSECA, JINGCHUAN GUO, HUI SHAO

Diabetes 2022;71(Supplement_1):418-P

https://doi.org/10.2337/db22-418-P

Published: 01 June 2022

View article titled, 418-P: Certain Patient Subgroups with Type 2 Diabetes May Benefit from Intensive Glycemic and Blood Pressure Control from Reductions in Major Adverse Cardiovascular Events (MACE) : A Machine Learning–Based Post Hoc Analysis of ACCORD Trial Data

Meeting Abstracts

1080-P: Sex-Specific Associations between Risk-Factor Control and Incident CVD in Diabetic Patients

XUAN WANG, HAO MA, VIVIAN FONSECA, LU QI

Diabetes 2022;71(Supplement_1):1080-P

https://doi.org/10.2337/db22-1080-P

Published: 01 June 2022

View article titled, 1080-P: Sex-Specific Associations between Risk-Factor Control and Incident CVD in Diabetic Patients

Meeting Abstracts

817-P: Identifying Modulators of Treatment Benefits of Albiglutide (GLP-1 RA) in Preventing Major Adverse Cardiovascular Events (MACE) among Individuals with Type 2 Diabetes in the HARMONY Trial Using Machine Learning

HAMED KIANMEHR, YILU LIN, LIZHENG SHI, VIVIAN FONSECA, JINGCHUAN GUO, HUI SHAO

Diabetes 2022;71(Supplement_1):817-P

https://doi.org/10.2337/db22-817-P

Published: 01 June 2022

View article titled, 817-P: Identifying Modulators of Treatment Benefits of Albiglutide (GLP-1 RA) in Preventing Major Adverse Cardiovascular Events (MACE) among Individuals with Type 2 Diabetes in the HARMONY Trial Using Machine Learning

Meeting Abstracts

174-OR: Identify Effect Modulators of Intensive Glucose Control in Preventing Cognitive Function Decline among Individuals with Type 2 Diabetes: A Revisit to the ACCORD MIND Trial

HAMED KIANMEHR, JINGCHUAN GUO, VIVIAN FONSECA, LIZHENG SHI, HUI SHAO

Diabetes 2022;71(Supplement_1):174-OR

https://doi.org/10.2337/db22-174-OR

Published: 01 June 2022

View article titled, 174-OR: Identify Effect Modulators of Intensive Glucose Control in Preventing Cognitive Function Decline among Individuals with Type 2 Diabetes: A Revisit to the ACCORD MIND Trial

Meeting Abstracts

659-P: Long-Term Health Benefit and Economic Return of Time in Range (TIR) Improvement in Individuals with Type 2 Diabetes

KHALID ALKHUZAM, LIZHENG SHI, VIVIAN FONSECA, YONGKANG ZHANG, JINGCHUAN GUO, HUI SHAO

Diabetes 2022;71(Supplement_1):659-P

https://doi.org/10.2337/db22-659-P

Published: 01 June 2022

View article titled, 659-P: Long-Term Health Benefit and Economic Return of Time in Range (TIR) Improvement in Individuals with Type 2 Diabetes

NARROW

Proteomic Signature of BMI and Risk of Type 2 Diabetes

152-OR: Sex Differences in Metabolomics and Risk of Coronary Heart Disease in Type 2 Diabetes

916-P: SGLT2 Inhibitors and Parkinson’s Disease (PD) Risk in Older Populations with Type 2 Diabetes (T2D)

1047-P: Estimating QALY-Based Price Ranges for Diabetes Drugs under IRA Negotiation

1269-P: Cumulative Effect of Early-Onset Type 2 Diabetes on Cardiac Dysfunction—The Coronary Artery Risk Development in Young Adults (CARDIA) Study

560-P: Optimizing Vision Care for Diabetes Patients—Interprofessional Initiatives to Combat Clinical Inertia in the Management of Diabetic Retinopathy and Diabetic Macular Edema

1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes—Soli De-escalation

829-P: Outcomes with Finerenone in People with CKD and T2D by Baseline Insulin Resistance—A FIDELITY Subgroup Analysis

1005-P: Developing a Machine-Learning–Based Prediction Model for Diabetes Duration Using Information from Electronic Health Records

1225-P: Biomarkers in Prediabetes Reflecting Sex Varying Pathways of Cardiovascular Risk

881-P: Heterogenous Effects of SGLT2 Inhibitors on Nephrolithiasis in Older Adults with Type 2 Diabetes

1006-P: Distributional Cost-Effectiveness Analysis of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) and Tirzepatide Compared with Sulfonylureas (SU) in People with Inadequately Controlled Type 2 Diabetes (T2D)

1352-P: Ethnic Disparities in Diabetic Complications in the U.S.

824-P: Glycemic Improvement, Insulin Reductions, and Improved Body Weight 48 Weeks after Revita Duodenal Mucosal Resurfacing in T2D patients with Previously Inadequately Controlled Glucose Despite Multiple Glucose-Lowering Agents Including Insulin

1196-P: Sex Difference in the Progression of Metabolic Syndrome Severity from Normoglycemia, Prediabetes, to Diabetes

418-P: Certain Patient Subgroups with Type 2 Diabetes May Benefit from Intensive Glycemic and Blood Pressure Control from Reductions in Major Adverse Cardiovascular Events (MACE) : A Machine Learning–Based Post Hoc Analysis of ACCORD Trial Data

1080-P: Sex-Specific Associations between Risk-Factor Control and Incident CVD in Diabetic Patients

817-P: Identifying Modulators of Treatment Benefits of Albiglutide (GLP-1 RA) in Preventing Major Adverse Cardiovascular Events (MACE) among Individuals with Type 2 Diabetes in the HARMONY Trial Using Machine Learning

174-OR: Identify Effect Modulators of Intensive Glucose Control in Preventing Cognitive Function Decline among Individuals with Type 2 Diabetes: A Revisit to the ACCORD MIND Trial

659-P: Long-Term Health Benefit and Economic Return of Time in Range (TIR) Improvement in Individuals with Type 2 Diabetes

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only